CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

(2009) D. Dornan et al.   BLOOD

Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas

(2009) Grazyna Fedorowicz et al.   BMC Medical Genomics

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells

(2009) Saritha Kusam et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

(2008) K. H. Young et al.   BLOOD

Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

(2008) Cornelia Hömig-Hölzel et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

(2008) Yujin Hoshida et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

Essential Cytoplasmic Translocation of a Cytokine Receptor-Assembled Signaling Complex

(2008) A. Matsuzawa et al.   SCIENCE